PetVivo Engages Former Dechra North American President, Mike Eldred as Commercial and Operations Advisor
PetVivo Holdings (OTCQB: PETV) has appointed Mike Eldred as Commercialization and Operations Advisor and Executive Director. Eldred brings 30 years of executive experience in animal health, notably serving as President of Dechra Pharmaceutical's North American Operations for 20 years, where he grew the subsidiary to over 250 employees and $400M+ in revenue.
The appointment aims to accelerate the adoption of Spryng™, PetVivo's intra-articular injectable veterinary medical device. Spryng uses OsteoCushion Technology, comprising sterilized extra-cellular matrix microparticles that integrate with animal subsynovial tissue to promote proper joint mechanics. Clinical studies have shown Spryng's effectiveness in treating lameness and joint-related conditions.
Prior to joining PetVivo, Eldred held senior positions at Virbac , Fort Dodge Animal Health, and Sanofi Animal Health, where he demonstrated success in business development, sales, and operations.
PetVivo Holdings (OTCQB: PETV) ha nominato Mike Eldred come Consulente per la Commercializzazione e le Operazioni e Direttore Esecutivo. Eldred porta con sé 30 anni di esperienza dirigenziale nella salute animale, avendo servito come Presidente delle Operazioni Nordamericane di Dechra Pharmaceutical per 20 anni, durante i quali ha fatto crescere la filiale a oltre 250 dipendenti e ricavi superiori a 400 milioni di dollari.
La nomina mira ad accelerare l'adozione di Spryng™, il dispositivo medico veterinario iniettabile intra-articolare di PetVivo. Spryng utilizza la Tecnologia OsteoCushion, composta da microparticelle di matrice extracellulare sterilizzate che si integrano con il tessuto subsinoviale degli animali per promuovere meccaniche articolari corrette. Gli studi clinici hanno dimostrato l'efficacia di Spryng nel trattamento della zoppia e delle condizioni articolari correlate.
Prima di unirsi a PetVivo, Eldred ha ricoperto posizioni senior in Virbac, Fort Dodge Animal Health e Sanofi Animal Health, dove ha dimostrato successo nello sviluppo commerciale, nelle vendite e nelle operazioni.
PetVivo Holdings (OTCQB: PETV) ha nombrado a Mike Eldred como Asesor de Comercialización y Operaciones y Director Ejecutivo. Eldred aporta 30 años de experiencia ejecutiva en salud animal, habiendo servido como Presidente de las Operaciones de Dechra Pharmaceutical en América del Norte durante 20 años, donde hizo crecer la filial a más de 250 empleados y más de 400 millones de dólares en ingresos.
La designación tiene como objetivo acelerar la adopción de Spryng™, el dispositivo médico veterinario inyectable intra-articular de PetVivo. Spryng utiliza la Tecnología OsteoCushion, que comprende micropartículas de matriz extracelular esterilizadas que se integran con el tejido subsinovial del animal para promover una mecánica articular adecuada. Los estudios clínicos han demostrado la efectividad de Spryng en el tratamiento de la cojera y las condiciones relacionadas con las articulaciones.
Antes de unirse a PetVivo, Eldred ocupó puestos de alto nivel en Virbac, Fort Dodge Animal Health y Sanofi Animal Health, donde demostró éxito en el desarrollo empresarial, ventas y operaciones.
PetVivo Holdings (OTCQB: PETV)는 Mike Eldred를 상업화 및 운영 자문가 겸 전무 이사로 임명했습니다. Eldred는 동물 건강 분야에서 30년의 경영 경험을 보유하고 있으며, Dechra Pharmaceutical의 북미 운영의 사장으로 20년 동안 근무하면서 자회사를 250명 이상의 직원과 4억 달러 이상의 수익을 올리는 규모로 성장시켰습니다.
이번 임명은 PetVivo의 관절 내 주사형 수의학 기기인 Spryng™의 채택을 가속화하기 위해 이루어졌습니다. Spryng은 동물의 피막막 조직과 결합하여 관절 기계 작동을 촉진하는 멸균된 세포외 기질 미세입자로 구성된 OsteoCushion 기술을 사용합니다. 임상 연구는 Spryng이 절름발이와 관절 관련 질환 치료에 효과적이라는 것을 보여주었습니다.
PetVivo에 합류하기 전, Eldred는 Virbac, Fort Dodge Animal Health 및 Sanofi Animal Health에서 주요 직책을 역임하며 비즈니스 개발, 판매 및 운영에서 성공을 거두었습니다.
PetVivo Holdings (OTCQB: PETV) a nommé Mike Eldred en tant que Conseiller en commercialisation et opérations et Directeur exécutif. Eldred possède 30 ans d'expérience exécutive dans le domaine de la santé animale, ayant notamment été Président des opérations nord-américaines de Dechra Pharmaceutical pendant 20 ans, période durant laquelle il a développé la filiale jusqu'à plus de 250 employés et plus de 400 millions de dollars de revenus.
Cette nomination vise à accélérer l'adoption de Spryng™, le dispositif médical vétérinaire injectable intra-articulaire de PetVivo. Spryng utilise la technologie OsteoCushion, composée de microparticules de matrice extracellulaire stérilisées qui s'intègrent au tissu sous-synovial des animaux afin de promouvoir une mécanique articulaire appropriée. Des études cliniques ont montré l'efficacité de Spryng dans le traitement des boiteries et des pathologies articulaires.
Avant de rejoindre PetVivo, Eldred a occupé des postes de direction chez Virbac, Fort Dodge Animal Health et Sanofi Animal Health, où il a démontré son succès dans le développement commercial, les ventes et les opérations.
PetVivo Holdings (OTCQB: PETV) hat Mike Eldred zum Berater für Kommerzialisierung und Betrieb sowie zum geschäftsführenden Direktor ernannt. Eldred bringt 30 Jahre Erfahrung in der Tiergesundheit mit, darunter 20 Jahre als Präsident der nordamerikanischen Tochtergesellschaft von Dechra Pharmaceutical, wo er die Tochtergesellschaft auf über 250 Mitarbeiter und über 400 Millionen Dollar Umsatz ausbaute.
Die Ernennung zielt darauf ab, die Akzeptanz von Spryng™, dem intraartikulären injizierbaren Veterinärgerät von PetVivo, zu beschleunigen. Spryng nutzt die OsteoCushion-Technologie, die aus sterilisierten extrazellulären Matrixmikropartikeln besteht, die sich mit tierischem subsynovialem Gewebe integrieren, um die ordnungsgemäße Gelenkmechanik zu fördern. Klinische Studien haben die Wirksamkeit von Spryng bei der Behandlung von Lahmheiten und gelenkbezogenen Erkrankungen gezeigt.
Bevor er zu PetVivo kam, bekleidete Eldred Führungspositionen bei Virbac, Fort Dodge Animal Health und Sanofi Animal Health, wo er Erfolge im Bereich Geschäftsentwicklung, Vertrieb und Betrieb nachgewiesen hat.
- Appointment of highly experienced executive with proven track record in animal health industry
- New advisor previously grew Dechra's North American operations to $400M+ in revenue
- Clinical studies demonstrate Spryng's effectiveness in treating joint conditions
- New executive brings extensive M&A experience (15+ commercial agreements at Dechra)
- None.
PetVivo Board Appoints Eldred as Executive Director to Lead Company
Product Commercialization and Operations
MINNEAPOLIS, MN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Mike Eldred as the Company’s Commercialization and Operations Advisor. His appointment as an Executive Director by the Company’s Board of Directors draws upon Mr. Eldred’s 30 years of executive experience in animal health and the veterinary industry to ramp up its product development and sales efforts.
For the past 20 years, Mr. Eldred served as President of North American Operations for Dechra Pharmaceutical, a global specialist in veterinary pharmaceuticals. He built Dechra’s North American subsidiary from the ‘ground up’ to become one of the fastest growing companies in the industry, with more than 250 employees and revenue in excess of
“Mike’s experience and proven record of business achievement in the animal health market brings to our Board a valuable resource for achieving our business goals,” PetVivo CEO, John Lai. “We anticipate his significant knowledge and extensive background in the veterinary space will help drive and accelerate the growing adoption of Spryng.”
Prior to Dechra, Eldred held senior positions in business development, sales and operations at Virbac Corporation, Fort Dodge Animal Health and Sanofi Animal Health.
Eldred commented, “I have closely followed PetVivo over the past few years, and I’m impressed with the company’s growth strategy and their innovative veterinary medical device - Spryng™, with OsteoCushion Technology. I’m excited to take a more active role at this pivotal time to help the company grow and expand the usage of Syrnge in the US equine and companion animal markets.”
Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles that have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
In multiple independent clinical studies, Spryng has been shown to improve the medical outcomes of animals suffering from lameness and other joint related afflictions.
Mike Eldred Bio
Eldred previously served as President of North American Operations at Dechra. He joined Dechra in 2004 and was responsible for Dechra Veterinary Products' North American business. He was Dechra’s first employee in the U.S., where he built the North American subsidiary to more than 250 people and sales in excess of
He was involved in more than 15 commercial agreements and acquisitions for Dechra, including Pharmaderm, DermaPet, Phycox Animal Health and Putney.
Prior to Dechra, he served as Director of Business Development and Corporate Business Unit at Virbac Corporation, an animal health pharmaceutical company. At Virbac, he directed and coordinated all acquisition, divestiture, licensing agreements, and business alliances strategic to the company. He was involved with such acquisitions as King Pharmaceutical’s animal health products and Delmarva Laboratories.
He previously served as Virbac’s Director of Supply Chain and Customer Service, where he reduced order turnaround time from five days to one day as well as improved customer fill rate form
Earlier, he served as director of Asia Pacific Poultry & North America Planning and Distribution at Fort Dodge Animal Health, a leading global manufacturer of animal health products for the livestock, companion animal, equine, swine, and poultry industries.
He also previously held senior positions at Garmin International and Sanofi Animal Health.
Eldred holds a BA in business from the University of Northern Iowa, and an MBA from University of Missouri-Kansas City.
About Spryng™ with OsteoCushion™ Technology
A revolutionary veterinary medical device that is transforming joint health for animals nationwide. The unique injectable medical device has garnered widespread attention for its effectiveness in the management of osteoarthritis and other musculoskeletal conditions.
In multiple independent clinical studies, Spryng has been shown to improve the medical outcomes of animals suffering from lameness and other joint related afflictions.
By mimicking and reinforcing natural joint cartilage, Spryng represents a highly effective, drug-free option for veterinarians looking for long-term solutions that can improve the mobility and quality of life for equines and companion animals.
The increasing success of Spryng is reflective of the fast-growing U.S. animal health market, which is projected to double to
For more information about Spryng, please contact info1@petvivo.com or visit petvivo.com and sprynghealth.com.
To learn more about PetVivo as a publicly traded company, contact John Lai at jlai@petvivo.com.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for equines and companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of equines and companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company’s commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
FAQ
What is Mike Eldred's role at PetVivo (PETV)?
What are Mike Eldred's achievements at Dechra Pharmaceuticals?
What is PetVivo's Spryng technology used for?
How effective is PETV's Spryng in treating animal joint conditions?
